Nanobiotix (NASDAQ:NBTX) Shares Gap Up on Analyst Upgrade

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Monday after Guggenheim raised their price target on the stock from $8.00 to $26.00. The stock had previously closed at $20.85, but opened at $22.36. Guggenheim currently has a buy rating on the stock. Nanobiotix shares last traded at $22.1650, with a volume of 2,737 shares changing hands.

A number of other analysts have also commented on the company. TD Cowen initiated coverage on Nanobiotix in a report on Friday. They issued a “buy” rating for the company. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a report on Saturday, October 25th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by institutional investors.

Nanobiotix Stock Performance

The stock’s 50-day simple moving average is $21.82 and its two-hundred day simple moving average is $17.74.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.